279 related articles for article (PubMed ID: 32067534)
1. A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK.
Pollock RF; Colaone F; Guardiola L; Shergill S; Brennan VK
J Med Econ; 2020 Jun; 23(6):593-602. PubMed ID: 32067534
[No Abstract] [Full Text] [Related]
2. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Wang EA; Stein JP; Bellavia RJ; Broadwell SR
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
4. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
Trials; 2014 Dec; 15():474. PubMed ID: 25472660
[TBL] [Abstract][Full Text] [Related]
5. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.
Walton M; Wade R; Claxton L; Sharif-Hurst S; Harden M; Patel J; Rowe I; Hodgson R; Eastwood A
Health Technol Assess; 2020 Sep; 24(48):1-264. PubMed ID: 33001024
[TBL] [Abstract][Full Text] [Related]
6. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
[TBL] [Abstract][Full Text] [Related]
7. The SIRveNIB and SARAH trials and the role of SIR-Spheres® Y-90 resin microspheres in the management of hepatocellular carcinoma.
Chow PK; Gandhi M; Gebski V
Future Oncol; 2017 Oct; 13(25):2213-2216. PubMed ID: 28976206
[No Abstract] [Full Text] [Related]
8. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.
Ricke J; Klümpen HJ; Amthauer H; Bargellini I; Bartenstein P; de Toni EN; Gasbarrini A; Pech M; Peck-Radosavljevic M; Popovič P; Rosmorduc O; Schott E; Seidensticker M; Verslype C; Sangro B; Malfertheiner P
J Hepatol; 2019 Dec; 71(6):1164-1174. PubMed ID: 31421157
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma.
Muszbek N; Remak E; Evans R; Brennan VK; Colaone F; Shergill S; Mullan D; Ross PJ
Future Oncol; 2021 Mar; 17(9):1055-1068. PubMed ID: 33222542
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness of selective internal radiation therapy with Y-90 resin microspheres for intermediate- and advanced-stage hepatocellular carcinoma in Brazil.
Agirrezabal I; Pereira Grillo Junior LS; Nasser F; Brennan VK; Bugano D; Galastri FL; da-Silva ALFA; Shergill S; da Motta-Leal-Filho JM
J Med Econ; 2023; 26(1):731-741. PubMed ID: 37139828
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
12. A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials.
Pollock RF; Brennan VK; Shergill S; Colaone F
Expert Rev Anticancer Ther; 2021 Mar; 21(3):341-349. PubMed ID: 33131346
[TBL] [Abstract][Full Text] [Related]
13. A cost-utility analysis of SIR-Spheres Y-90 resin microspheres versus best supportive care in the treatment of unresectable metastatic colorectal cancer refractory to chemotherapy in the UK.
Brennan VK; Colaone F; Shergill S; Pollock RF
J Med Econ; 2020 Dec; 23(12):1588-1597. PubMed ID: 33084466
[TBL] [Abstract][Full Text] [Related]
14. Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study.
Palmer DH; Hawkins NS; Vilgrain V; Pereira H; Chatellier G; Ross PJ
Future Oncol; 2020 Jan; 16(1):4315-4325. PubMed ID: 31797680
[No Abstract] [Full Text] [Related]
15. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman OM; Elsayed Z
Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Adverse Event Profile of TheraSphere
Kallini JR; Gabr A; Thorlund K; Balijepalli C; Ayres D; Kanters S; Ebrahim S; Mills E; Lewandowski RJ; Salem R
Cardiovasc Intervent Radiol; 2017 Jul; 40(7):1033-1043. PubMed ID: 28246879
[TBL] [Abstract][Full Text] [Related]
17. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma.
Kolligs FT; Bilbao JI; Jakobs T; Iñarrairaegui M; Nagel JM; Rodriguez M; Haug A; D'Avola D; op den Winkel M; Martinez-Cuesta A; Trumm C; Benito A; Tatsch K; Zech CJ; Hoffmann RT; Sangro B
Liver Int; 2015 Jun; 35(6):1715-21. PubMed ID: 25443863
[TBL] [Abstract][Full Text] [Related]
18. The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres.
Pardo F; Sangro B; Lee RC; Manas D; Jeyarajah R; Donckier V; Maleux G; Pinna AD; Bester L; Morris DL; Iannitti D; Chow PK; Stubbs R; Gow PJ; Masi G; Fisher KT; Lau WY; Kouladouros K; Katsanos G; Ercolani G; Rotellar F; Bilbao JI; Schoen M
Ann Surg Oncol; 2017 Sep; 24(9):2465-2473. PubMed ID: 28653161
[TBL] [Abstract][Full Text] [Related]
19. Selective internal radiation therapy with yttrium-90 resin microspheres followed by anatomical hepatectomy: A potential curative strategy in advanced hepatocellular carcinoma.
Feng X; Zhang L; Niu H; Zhang H; Yang L; Wen Y; Chen SY; Shi Y; He Z; Yu L; Wang Y; Huang X; Wang Z; Qin M; Wen X; Zhang Z; Song J; Zheng Z; Yin H; Zhang H; Ma L; Wei J; Wu X; Zhang L; Zhao Y; Lu Q; Xiao H; Liu T; Fang P; Wei L; Gandhi RT; Dong J
Asia Pac J Clin Oncol; 2024 Apr; 20(2):319-322. PubMed ID: 36658669
[TBL] [Abstract][Full Text] [Related]
20. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
